Abstract Library

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#4409 The value of NETest 2.0 in stratifying patients with suspected NEN for formal diagnostic evaluation – Real-world data

Introduction: An unmet need in NEN diagnosis is better risk stratification for individuals with suspected disease (based on symptoms or imaging), enabling efficient identification of those needing further evaluation and tissue diagnosis, thus speeding the process and reducing costs. NETest 2.0, a biomarker based on a 51-gene mRNA panel, was developed for diagnosing neuroendocrine neoplasia (NEN).

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, at-risk population, NEN,

#3794 Impact of gender on treatment decisions and outcome in patients with neuroendocrine neoplasms

Introduction: Gender differences affect the treatment of several diseases in both male and female patients. However, the influence of gender on treatment decisions and outcome in neuroendocrine neoplasms (NENs) has scarcely been investigated.

Conference:

Presenting Author: Beck J

Authors: Beck J, Siebenhüner A, Wild D, Christ E, Refardt J,

Keywords: gender bias, registry, survival analysis,

#3783 Impact on clinical management of a novel blood-derived liquid biopsy (NETest) in patients with neuroendocrine tumors

Introduction: Despite progresses in NET management, there are persisting challenges regarding initial diagnosis, treatment response assessment and disease follow-up.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, de Dosso S, Wild D, Siebenhüner A, Voegeli M,

Keywords: transcriptomics, biomarker, NETest, clinical management, NET,

#3720 Efficacy of somatostatin analogues (SSA) in G3 neuroendocrine neoplasms – A comprehensive analysis among the SwissNET cohort

Introduction: G3 differentiated neuroendocrine neoplasms (NEN) are divided into G3 NET and NEC depending on their histological appearance and proliferation index. The literature on different systemic treatment options in these G3 entities is scarce especially for use of somatostatin analogues (SSA).

Conference:

Presenting Author: Siebenhüner A

Authors: Siebenhüner A, Christ E, Kollar A,

Keywords: neuroendocrine neoplasm, neuroendocrine tumor G3, neuroendocrine carcinoma G3, registry, somatostatin analogues, survival,